The Blueprint Neurotherapeutics Network for Small Molecule (BPN-Small Molecule), which provides non-dilutive support for small molecule drug discovery and development, from hit-to-lead chemistry through phase I clinical testing, held a Q&A Webinar for potential applicants on Thursday, April 14, 2022. Program Director Dr. Charles Cywin provided an overview of the program and answered questions about the application process.

PAR-20-111 Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

PAR-20-122 Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

Next Receipt date for both BPN-Small Molecule Funding Opportunities is August 9th, 2022

свернуть